Inmune Bio names James Sapirstein director

Inmune Bio, Inc. (INMB) has a new Form 3 on file identifying James Sapirstein as a director and reporting person with respect to the company’s equity securities.

Available on EDGAR 09/16/2026 - 08:05 PM EDT Accepted by SEC EDGAR 09/16/2026 - 08:05 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Inmune Bio, Inc. (INMB) has a new Form 3 on file identifying James Sapirstein as a director and reporting person with respect to the company’s equity securities. The filing, as summarized here, does not list any specific share or derivative holdings or any reportable transactions.

Key Terms

Form 3, reporting person, beneficial ownership

3 terms

Form 3 regulatory

"new Form 3 on file identifying James Sapirstein as a director"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

reporting person regulatory

"identifying James Sapirstein as a director and reporting person"

beneficial ownership financial

"does not list any specific share or derivative holdings or beneficial ownership"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does INMB’s new Form 3 for James Sapirstein disclose?

It identifies James Sapirstein as a director and reporting person for Inmune Bio, Inc. The summary data includes no reported transactions and no specific share or derivative positions for him in this filing snapshot.

Are any INMB share purchases or sales reported for James Sapirstein on this Form 3?

No. The transaction summary shows no buy or sell transactions, and no other acquisitions, dispositions, or derivative exercises are reported for James Sapirstein on this Form 3 snapshot.

Does the INMB Form 3 show how many shares James Sapirstein owns?

No. The summary data indicates no holding entries and does not state any specific number of Inmune Bio shares or derivatives beneficially owned by James Sapirstein in this filing excerpt.

Is there any Rule 10b5-1 trading plan noted for James Sapirstein in the INMB Form 3?

No. The available data show the Rule 10b5-1 plan status field as null, meaning the Form 3 predates the standardized checkbox; no plan is described in the structured summary provided.

What is James Sapirstein’s role at Inmune Bio according to this Form 3?

The Form 3 identifies James Sapirstein as a director of Inmune Bio, Inc. and a reporting person with respect to the company’s equity securities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

SAPIRSTEIN JAMES

(Last) (First) (Middle)

C/O INMUNE BIO INC.

225 NE MIZNER BLVD., SUITE 640

(Street)

BOCA RATON FLORIDA 33432

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
09/08/2026

3. Issuer Name and Ticker or Trading Symbol
Inmune Bio, Inc. [ INMB ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ James Sapirsten	09/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)